Treatment Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Please complete Pre-test
Chapter 1 of 3
Release Date: October 16, 2020
Expiration Date: October 16, 2021
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
This activity was previously presented between October 05 and 13, 2020 as a live webinar. Please note: If you participated in one of the live webinars, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are challenging for healthcare providers to treat and manage, partly because of the complexities surrounding diagnosis and prognosis, and because most patients are older. In this activity, two experts review cytogenetic and molecular abnormalities in AML and MDS, types of testing, and novel targets of treatment. They will also discuss case vignettes that support best practice for patients with AML and MDS.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with AML or MDS.
Upon completion of this educational activity, participants should be able to:
- Apply updated recommendations for diagnostic and prognostic evaluation of AML and MDS in clinical practice, including optimal use of cytogenetic and molecular testing
- Incorporate new and emerging therapies into the treatment paradigm to provide optimal care for patients with newly diagnosed or relapsed/refractory AML
- Develop individualized treatment plans for patients with AML based on age, risk assessment, and other patient- or disease-related factors
- Manage anemia and other disease-related conditions in elderly patients with MDS
Chapter 1 - Diagnostic, Prognostic and Therapeutic Importance of Cytogenetic and Molecular Abnormalities in AML and MDS – Vijaya Bhatt, MD and Mikkael Sekeres, MD
Chapter 2 - The Treatment Landscape for AML and MDS: Current and Emerging Therapies – Vijaya Bhatt, MD and Mikkael Sekeres, MD
Chapter 3 - Case Discussions: Newly Diagnosed AML, Relapsed/Refractory AML, Lower-risk MDS, and Higher-risk MDS – Vijaya Bhatt, MD and Mikkael Sekeres, MD
Instructions for Participation and Credit
This activity is eligible for credit through October 16, 2021. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Vijaya Raj Bhatt, MD
Medical Director, Leukemia Program
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Dr. Vijaya Raj Bhatt serves as a Medical Director of Leukemia Program and a Co-Leader of the Leukemia/Transplant Research Focus Group at the Fred and Pamela Buffett Cancer Center. He has played a leading role in the development of a Geriatric Leukemia and Transplant Program at the Buffett Cancer Center. As a co-chair, he led the Big Ten Cancer Research Consortium Myeloid Malignancies, and Stem Cell Transplant Working Groups. He also serves as a member of National Cancer Clinical Network (NCCN) Acute Myeloid Leukemia (AML) and Hematopoietic Cell Transplantation Guidelines Panels, and a member of the NCI’s Myeloid Malignancies Molecular Analysis for Therapy of Choice (myeloMATCH), Older Adult with Acute Myeloid Leukemia Working Group. Dr. Bhatt has participated in many investigator-initiated, industry-sponsored, and cooperative group-led transplant and leukemia trials and has authored 190 articles and 24 book chapters.
Mikkael A. Sekeres, MD
Professor of Medicine
Director, Leukemia Program
Vice Chair for Clinical Research
Cleveland Clinic Taussig Cancer Institute
Dr. Mikkael Sekeres earned a medical degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine. He completed his postgraduate training at Harvard University, finishing an internal medicine residency at Massachusetts General Hospital, and a fellowship in hematology-oncology at the Dana-Farber Cancer Institute in Boston. Dr. Sekeres is Professor of Medicine, Director of the Leukemia Program, and Vice Chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute. In addition, he is Deputy Associate Director for Clinical Research of the Case Comprehensive Cancer Center in Ohio.
Dr. Sekeres chaired the Oncologic Drugs Advisory Committee of the FDA and is chair of the medical advisory board of the Aplastic Anemia and Myelodysplastic Syndrome (MDS) International Foundation, the MDS Research Fund of the Dresner Foundation, and the Cleveland Clinic Enterprise Pharmacy & Therapeutics Committee. An invited speaker at numerous meetings, grand rounds, and conferences, Dr. Sekeres is a member of the American Society of Hematology, where he is also on the executive committee, the American Society of Clinical Oncology, and the Southwest Oncology Group—Leukemia Committee. His research focuses on patients with MDS and older adults with acute myeloid leukemia, and he has been the national and international primary study investigator on several phase I/II/III trials. Dr. Sekeres is the author/co-author of more than 350 manuscripts and 550 abstracts published in The New England Journal of Medicine, Blood, Journal of Clinical Oncology, Nature Genetics, Cancer Cell, Journal of the National Cancer Institute, Journal of Clinical Investigation, PLoS One, and Leukemia. He was the inaugural editor-in-chief of the ASH Clinical News magazine, is on the editorial board of several journals, has written more than 50 essays for The New York Times, and has authored seven books, including the newly released When Blood Breaks Down: Lessons from Leukemia.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by University of Nebraska Medical Center and MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals and Daiichi Sankyo.
©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. This activity is provided for 1.0 contact hour under ANCC criteria. Program #: 20CC147E
This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, University of Nebraska Medical Center College of Nursing Continuing Nursing Education and MediCom Worldwide, Inc.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-20-038-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME) and American Nurses Credentialing Center (ANCC), University of Nebraska Medical Center, Center for Continuing Education and University of Nebraska Medical Center, College of Nursing Continuing Nursing Education and as an organization accredited by the Accreditation Council for Pharmacy Education (ACPE), MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Vijaya Bhatt has received honoraria as a consultant from AbbVie Inc., Agios, Incyte Corporation, Omeros Corporation, Partnership for Health Analytic Research (funded by Jazz Pharmaceuticals plc), Rigel Pharmaceuticals, Inc., and Takeda Oncology. He has received grant support related to research activities from AbbVie, Incyte, Jazz, National Marrow Donor Program, Pfizer Inc., and Tolero Pharmaceuticals. He has also disclosed a financial relationship with Oncoceutics, Inc.
Dr. Mikkael Sekeres has received honoraria related to formal advisory activities from Bristol-Myers Squibb Company and Celgene Corporation – A Bristol-Myers Squibb Company.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.
The individuals listed below from the University of Nebraska Medical Center reported the following for this activity: Brenda Ram, CMP, CHCP, Director, Educational Programs, UNMC Center for Continuing Education, Heidi Keeler, PhD, RN, Lead Nurse Planner/Director and Renee Paulin, MSN, RN, CWOCN, Nurse Planner, UNMC College of Nursing Continuing Nursing Education, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
- Chapter 1: Diagnostic, Prognostic and Therapeutic Importance of Cytogenetic and Molecular Abnormalities in AML and MDS – Run Time: 12:32
- Chapter 2: The Treatment Landscape for AML and MDS: Current and Emerging Therapies – Run Time: 24:58
- Chapter 3: Case Discussions: Newly Diagnosed AML, Relapsed/Refractory AML, Lower-risk MDS, and Higher-risk MDS – Run Time: 20:55
- Assessment and Evaluation